

Eric C Strain

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1668603/eric-c-strain-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144
papers

6,514
citations

39
h-index

78
g-index

162
ext. papers

7,376
ext. citations

5.5
avg, IF

5.75
L-index

#	Paper	IF	Citations
144	Characterization of basal ganglia volume changes in the context of HIV and polysubstance use.. <i>Scientific Reports</i> , 2022 , 12, 4357	4.9	0
143	A comparison of registered and published primary outcomes in clinical trials of opioid use disorder: ACTION review and recommendations.. <i>Drug and Alcohol Dependence</i> , 2022 , 236, 109447	4.9	
142	Objective sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review. <i>Drug and Alcohol Dependence</i> , 2022 , 109509	4.9	2
141	Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D. <i>Journal of Addiction Medicine</i> , 2021 , 15, 325-333	3.8	1
140	Electronic health record adoption among US substance use disorder and other mental health treatment facilities. <i>Drug and Alcohol Dependence</i> , 2021 , 220, 108515	4.9	2
139	Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2021 , 221, 108649	4.9	
138	Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. <i>Pain</i> , 2021 , 162, 2669-2681	8	3
137	Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility. <i>Experimental and Clinical Psychopharmacology</i> , 2021 ,	3.2	2
136	Moving Beyond Medications That Act at the μ Receptor in the Treatment of Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2021 , 78, 701-702	14.5	1
135	Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. <i>American Journal on Addictions</i> , 2021 , 30, 83-87	3.7	20
134	News and social media coverage is associated with more downloads and citations of manuscripts that focus on substance use. <i>Drug and Alcohol Dependence</i> , 2021 , 218, 108357	4.9	1
133	Symptom severity and medication-assisted treatment for individuals with serious mental illness and a history of heroin use. <i>Psychiatry Research</i> , 2021 , 296, 113671	9.9	
132	A preliminary examination of the multiple dimensions of opioid craving. <i>Drug and Alcohol Dependence</i> , 2021 , 219, 108473	4.9	1
131	Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. <i>Drug and Alcohol Dependence</i> , 2021 , 226, 108869	4.9	1
130	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020 , 212, 107993	4.9	25
129	Integrated dual diagnosis treatment among United States mental health treatment facilities: 2010 to 2018. <i>Drug and Alcohol Dependence</i> , 2020 , 213, 108074	4.9	4
128	Protracted renal clearance of fentanyl in persons with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2020 , 214, 108147	4.9	17

127	Drug Legalization and Decriminalization Beliefs Among Substance-using and Nonusing Individuals. <i>Journal of Addiction Medicine</i> , 2020 , 14, 56-62	3.8	2
126	Relationship between cannabis use frequency and major depressive disorder in adolescents: Findings from the National Survey on Drug Use and Health 2012-2017. <i>Drug and Alcohol Dependence</i> , 2020 , 208, 107867	4.9	12
125	Experimental sleep disruption attenuates morphine analgesia: findings from a randomized trial and implications for the opioid abuse epidemic. <i>Scientific Reports</i> , 2020 , 10, 20121	4.9	5
124	Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. <i>Drug and Alcohol Dependence</i> , 2020 , 215, 108212	4.9	2
123	A Randomized and Controlled Acceptability Trial of an Internet-based Therapy among Inpatients with Co-occurring Substance Use and Other Psychiatric Disorders. <i>Journal of Dual Diagnosis</i> , 2020 , 16, 447-454	2.4	3
122	Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. <i>Addiction Biology</i> , 2020 , 25, e12680	4.6	13
121	Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals. <i>Anesthesiology</i> , 2019 , 130, 131-141	4.3	11
120	Medical Devices to Prevent Opioid Use Disorder: Innovative Approaches to Addressing the Opioid Crisis. <i>JAMA Psychiatry</i> , 2019 , 76, 351-352	14.5	2
119	What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?. <i>Addiction</i> , 2019 , 114, 9-15	4.6	36
118	The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal. <i>Drug and Alcohol Dependence</i> , 2019 , 202, 111-114	4.9	4
117	Time to Reconsider the Role of Craving in Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2019 , 76, 1113-1114	14.5	9
116	A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans. <i>Frontiers in Psychiatry</i> , 2019 , 10, 704	5	14
115	Craving and opioid use disorder: A scoping review. <i>Drug and Alcohol Dependence</i> , 2019 , 205, 107639	4.9	13
114	Trends in first-time treatment admissions for older adults with alcohol use disorder: Availability of medical and specialty clinical services in hospital, residential, and outpatient facilities. <i>Drug and Alcohol Dependence</i> , 2019 , 205, 107694	4.9	4
113	Differential adoption of opioid agonist treatments in detoxification and outpatient settings. <i>Journal of Substance Abuse Treatment</i> , 2019 , 107, 24-28	4.2	10
112	Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2019 , 194, 500-517	4.9	21
111	Response to commentaries: The quest(ion) remains in the search for a meaningful reduction-based end-point. <i>Addiction</i> , 2019 , 114, 21-23	4.6	
110	Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. <i>Alcoholism: Clinical and Experimental Research</i> , 2019 , 43, 158-169	3.7	26

109	Tramadol Extended-Release and Opioid Withdrawal Management-Legal Implications-Reply. <i>JAMA Psychiatry</i> , 2018 , 75, 215	14.5	
108	To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in self-identified chronic pain patients. <i>Addiction</i> , 2018 , 113, 67-79	4.6	8
107	Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. <i>Addictive Behaviors</i> , 2018 , 76, 8-14	4.2	31
106	Sex and age differences in risk factors of marijuana involvement during adolescence. <i>Addictive Disorders and Their Treatment</i> , 2018 , 17, 29-39	0.5	7
105	A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2018 , 193, 142-147	4.9	44
104	Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2017 , 74, 885-893	14.5	24
103	Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence. <i>Alcohol and Alcoholism</i> , 2017 , 52, 72-79	3.5	6
102	A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2017 , 42, 1012-1023	8.7	51
101	Age and gender considerations for technology-assisted delivery of therapy for substance use disorder treatment: A patient survey of access to electronic devices. <i>Addictive Disorders and Their Treatment</i> , 2016 , 15, 149-156	0.5	2
100	Measures of outcome for stimulant trials: ACTION recommendations and research agenda. <i>Drug and Alcohol Dependence</i> , 2016 , 158, 1-7	4.9	42
99	Prescriptions, nonmedical use, and emergency department visits involving prescription stimulants. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, e297-304	4.6	42
98	Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes. <i>Pain</i> , 2016 , 157, 1724-1732	8	12
97	Initial feasibility and validity of a prospective memory training program in a substance use treatment population. <i>Experimental and Clinical Psychopharmacology</i> , 2016 , 24, 390-399	3.2	4
96	Classifying substance use disorder treatment facilities with co-located mental health services: A latent class analysis approach. <i>Drug and Alcohol Dependence</i> , 2016 , 163, 108-115	4.9	11
95	Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers. <i>American Journal of Drug and Alcohol Abuse</i> , 2015 , 41, 251-6	3.7	8
94	Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTION Systematic Review. <i>Journal of Pain</i> , 2015 , 16, 389-411	5.2	21
93	A randomized controlled trial of the effects of working memory training in methadone maintenance patients. <i>Drug and Alcohol Dependence</i> , 2015 , 156, 38-46	4.9	61
92	Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. <i>Drug and Alcohol Dependence</i> , 2015 , 157, 143-9	4.9	29

91	Introduction. <i>Drug and Alcohol Dependence</i> , 2015 , 156, e1	4.9	
90	Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence. <i>Psychology of Addictive Behaviors</i> , 2015 , 29, 237-46	3.4	4
89	Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysis. <i>Addictive Disorders and Their Treatment</i> , 2015 , 14, 211-219	0.5	3
88	Patterns of concurrent substance use among adolescent nonmedical ADHD stimulant users. <i>Addictive Behaviors</i> , 2015 , 49, 1-6	4.2	14
87	Patterns of concurrent substance use among nonmedical ADHD stimulant users: results from the National Survey on Drug Use and Health. <i>Drug and Alcohol Dependence</i> , 2014 , 142, 86-90	4.9	13
86	Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. <i>Journal of Pain</i> , 2014 , 15, 321-37	5.2	163
85	Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. <i>Addictive Behaviors</i> , 2014 , 39, 829-36	4.2	30
84	Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level. <i>Experimental and Clinical Psychopharmacology</i> , 2014 , 22, 248-256	3.2	20
83	Sources of nonmedically used prescription stimulants: differences in onset, recency and severity of misuse in a population-based study. <i>Drug and Alcohol Dependence</i> , 2014 , 145, 106-12	4.9	14
82	The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males. <i>Clinical Journal of Pain</i> , 2014 , 30, 36-45	3.5	8
81	Employment-based abstinence reinforcement promotes opiate and cocaine abstinence in out-of-treatment injection drug users. <i>Journal of Applied Behavior Analysis</i> , 2014 , 47, 681-93	2.6	15
80	A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014 , 348, 217-26	4.7	28
79	Behavioural health interventions in the Johns Hopkins Community Health Partnership: integrated care as a component of health systems transformation. <i>International Review of Psychiatry</i> , 2014 , 26, 648-56	3.6	10
78	The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. <i>Preventive Medicine</i> , 2014 , 68, 62-70	4.3	19
77	Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2014 , 140, 92-100	4.9	35
76	Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing. <i>Drug and Alcohol Dependence</i> , 2013 , 132, 369-72	4.9	3
75	Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. <i>Psychiatric Services</i> , 2013 , 64, 863-70	3.3	68
74	Gender differences in substance abuse treatment and barriers to care among persons with substance use disorders with and without comorbid major depression. <i>Journal of Addiction Medicine</i> , 2013 , 7, 325-34	3.8	83

73	A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. <i>Journal of Addiction Medicine</i> , 2013 , 7, 277-86	3.8	173
72	Pretreatment alcohol drinking goals are associated with treatment outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2013 , 37, 1745-52	3.7	18
71	A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2012 , 36, 1421-30	3.7	38
70	Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence. <i>Drug and Alcohol Dependence</i> , 2012 , 124, 167-71	4.9	8
69	An fMRI investigation of cerebellar function during verbal working memory in methadone maintenance patients. <i>Cerebellum</i> , 2012 , 11, 300-10	4.3	24
68	Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. <i>Journal of Opioid Management</i> , 2012 , 8, 369-82	0.8	36
67	Drug use and sport--a commentary on: Injury, pain and prescription opioid use among former National Football League football players by Cottler et al. <i>Drug and Alcohol Dependence</i> , 2011 , 116, 8-10	4.9	2
66	The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. <i>Drug and Alcohol Dependence</i> , 2011 , 119, 1-9	4.9	48
65	A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. <i>Journal of Substance Abuse Treatment</i> , 2011 , 40, 255-64	4.2	33
64	Increased blood pressure after abrupt cessation of daily cannabis use. <i>Journal of Addiction Medicine</i> , 2011 , 5, 16-20	3.8	23
63	Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 443-9	6.1	38
62	Response to Commercial Factors Override Science in Combination Addiction Drug Trial <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 650-650	6.1	
61	Discriminative stimulus effects of tramadol in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 338, 255-62	4.7	31
60	The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. <i>American Journal of Drug and Alcohol Abuse</i> , 2010 , 36, 46-51	3.7	7
59	Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine. <i>Experimental and Clinical Psychopharmacology</i> , 2010 , 18, 305-15	3.2	6
58	Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center. <i>Journal of Substance Abuse Treatment</i> , 2010 , 39, 298-305	4.2	16
57	Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers. <i>Drug and Alcohol Dependence</i> , 2010 , 111, 265-8	4.9	26
56	Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. <i>Psychopharmacology</i> , 2010 , 210, 471-80	4.7	21

55	Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. <i>Psychopharmacology</i> , 2010 , 211, 303-12	4.7	18
54	Physical dependence potential of daily tramadol dosing in humans. <i>Psychopharmacology</i> , 2010 , 211, 457-66	4.7	49
53	Caffeinated energy drinks--a growing problem. <i>Drug and Alcohol Dependence</i> , 2009 , 99, 1-10	4.9	657
52	Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. <i>Drug and Alcohol Dependence</i> , 2009 , 105, 154-9	4.9	101
51	Screening for Mood Disorder in Pregnant Substance-dependent Patients. <i>Addictive Disorders and Their Treatment</i> , 2009 , 8, 88-98	0.5	3
50	Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. <i>American Journal on Addictions</i> , 2009 , 18, 422-9	3.7	21
49	Changing profile of abused substances by older persons entering treatment. <i>Journal of Nervous and Mental Disease</i> , 2008 , 196, 898-905	1.8	63
48	Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 850, 536-43	3.2	31
47	Experimentally-induced spontaneous opiate withdrawal: relationship to cigarette craving and expired air carbon monoxide. <i>American Journal on Addictions</i> , 2007 , 16, 310-5	3.7	2
46	Modest opioid withdrawal suppression efficacy of oral tramadol in humans. <i>Psychopharmacology</i> , 2007 , 194, 381-93	4.7	34
45	Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. <i>Drug and Alcohol Dependence</i> , 2007 , 90, 261-9	4.9	72
44	Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. <i>Journal of Substance Abuse Treatment</i> , 2007 , 33, 355-61	4.2	2
43	Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. <i>Psychopharmacology</i> , 2006 , 189, 297-306	4.7	18
42	Decreased frontal white-matter volume in chronic substance abuse. <i>International Journal of Neuropsychopharmacology</i> , 2006 , 9, 147-53	5.8	64
41	HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. <i>Journal of Substance Abuse Treatment</i> , 2006 , 31, 187-94	4.2	26
40	Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. <i>Experimental and Clinical Psychopharmacology</i> , 2006 , 14, 109-20	3.2	14
39	Treatment of patients with substance use disorders, second edition. American Psychiatric Association. <i>American Journal of Psychiatry</i> , 2006 , 163, 5-82	11.9	34
38	Characteristics of older opioid maintenance patients. <i>Journal of Substance Abuse Treatment</i> , 2005 , 28, 265-72	4.2	71

37	Comparative Safety and Side Effect Profiles of Buprenorphine and Methadone in the Outpatient Treatment of Opioid Dependence. <i>Addictive Disorders and Their Treatment</i> , 2005 , 4, 49-64	0.5	12
36	Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. <i>Experimental and Clinical Psychopharmacology</i> , 2005 , 13, 293-302	3.2	55
35	Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial. <i>American Journal on Addictions</i> , 2004 , 13, 421-37	3.7	12
34	Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. <i>Drug and Alcohol Dependence</i> , 2004 , 74, 37-43	4.9	61
33	A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. <i>Drug and Alcohol Dependence</i> , 2004 , 74, 205-9	4.9	32
32	Differences at Treatment Entry Between Opioid-Dependent and Cocaine-Dependent Males and Females. <i>Addictive Disorders and Their Treatment</i> , 2004 , 3, 110-121	0.5	3
31	Review: there is insufficient evidence for naltrexone maintenance treatment in opioid dependence. <i>Evidence-Based Mental Health</i> , 2003 , 6, 57	11.1	
30	Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. <i>Addiction</i> , 2003 , 98, 427-39	4.6	21
29	Single versus multiple drug focus in substance abuse clinical trials research: the devil is in the details. <i>Drug and Alcohol Dependence</i> , 2003 , 70, 131-4	4.9	3
28	Buprenorphine: how to use it right. <i>Drug and Alcohol Dependence</i> , 2003 , 70, S59-77	4.9	187
27	A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. <i>Analytical Biochemistry</i> , 2002 , 306, 31-9	3.1	113
26	Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. <i>Journal of General Internal Medicine</i> , 2002 , 17, 334-340	4	8
25	Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. <i>Psychopharmacology</i> , 2002 , 159, 161-6	4.7	39
24	Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. <i>Journal of General Internal Medicine</i> , 2002 , 17, 334-40	4	18
23	Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. <i>Clinical Journal of Pain</i> , 2002 , 18, S14-27	3.5	86
22	Voucher-based reinforcement of opiate abstinence during methadone detoxification. <i>Drug and Alcohol Dependence</i> , 2002 , 65, 179-89	4.9	45
21	Effects of buprenorphine/naloxone in opioid-dependent humans. <i>Psychopharmacology</i> , 2001 , 154, 230-42	4.7	132
20	Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. <i>Psychopharmacology</i> , 2001 , 157, 151-62	4.7	192

19	Gradual dose taper following chronic buprenorphine. <i>American Journal on Addictions</i> , 2001 , 10, 111-21	3.7	17
18	A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. <i>New England Journal of Medicine</i> , 2000 , 343, 1290-7	59.2	509
17	Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 281, 1000-5	27.4	286
16	Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. <i>American Journal of Psychiatry</i> , 1998 , 155, 470-3	11.9	114
15	Useful Predictors of Outcome in Methadone-Treated Patients. <i>Journal of Maintenance in the Addictions</i> , 1998 , 1, 15-28		11
14	Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. <i>Drug and Alcohol Dependence</i> , 1997 , 45, 81-91	4.9	33
13	Opioid antagonist effects of dezocine in opioid-dependent humans. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 206-17	6.1	13
12	Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 58-67	1.7	94
11	A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 1995 , 40, 17-25	4.9	156
10	Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. <i>Drug and Alcohol Dependence</i> , 1995 , 40, 27-35	4.9	81
9	Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. <i>Psychopharmacology</i> , 1994 , 116, 401-6	4.7	95
8	Outcome after methadone treatment: influence of prior treatment factors and current treatment status. <i>Drug and Alcohol Dependence</i> , 1994 , 35, 223-30	4.9	17
7	The Effects of Cocaine in Buprenorphine-Maintained Outpatient Volunteers:Results from Clinical Experience and Laboratory Challenges. <i>American Journal on Addictions</i> , 1994 , 3, 129-143	3.7	3
6	Methadone dose and treatment outcome. <i>Drug and Alcohol Dependence</i> , 1993 , 33, 105-17	4.9	90
5	Dose-response effects of methadone in the treatment of opioid dependence. <i>Annals of Internal Medicine</i> , 1993 , 119, 23-7	8	154
4	Withdrawal syndrome after the double-blind cessation of caffeine consumption. <i>New England Journal of Medicine</i> , 1992 , 327, 1109-14	59.2	334
3	Clustering of multiple substance use and psychiatric diagnoses in opiate addicts. <i>Drug and Alcohol Dependence</i> , 1991 , 27, 127-34	4.9	49
2	Intravenous drug abusers with antisocial personality disorder: increased HIV risk behavior. <i>Drug and Alcohol Dependence</i> , 1990 , 26, 39-44	4.9	77

- 1 Modulation of cellular immunity in medical students. *Journal of Behavioral Medicine*, **1986**, 9, 5-21 3.6 314